Enliven Therapeutics to present Phase 1 ENABLE trial data for ELVN-001 in CP-CML at SOHO 2026 - ELVN News | RalliesEnliven Therapeutics to present Phase 1 ENABLE trial data for ELVN-001 in CP-CML at SOHO 2026
E
ELVN• SOHO 2026 presentation planned for ELVN-001
- Enliven Therapeutics scheduled an encore data presentation from its ENABLE Phase 1 trial of ELVN-001 at SOHO 2026.
- Results were previously presented at the European Hematology Association 2026 Congress.
- SOHO oral session set for Sept. 10, 2026; poster session set for Sept. 9, 2026, in Houston.
- Trial evaluates ELVN-001 in previously treated chronic-phase CML, including patients with T315I mutations and those resistant or intolerant to TKIs.
- Update centers on safety, tolerability, drug exposure, and signs of clinical activity to support dose selection for further development.
XLE
•
